Biodesix Inc (BDSX) SEC filings

BDSXNasdaqServices-Medical LaboratoriesFiscal year ends December 31

Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 5, 2026Score 4/30

$9.79−0.33 (-3.26%)

Close on Nov 12, 2026Market cap $103.30MP/E –Yield –

SEC filings

40 of Biodesix's most recent filings on SEC EDGAR

Document	Form	Period	Filed	Source
Current report	8-K	Nov 2, 2026	Nov 5, 2026	SEC EDGAR
Quarterly report	10-Q	Sep 30, 2026	Nov 5, 2026	SEC EDGAR
Current report	8-K	Nov 5, 2026	Nov 5, 2026	SEC EDGAR
Quarterly report	10-Q	Jun 30, 2026	Aug 5, 2026	SEC EDGAR
Current report	8-K	Aug 5, 2026	Aug 5, 2026	SEC EDGAR
Current report	8-K	May 19, 2026	May 20, 2026	SEC EDGAR
Quarterly report	10-Q	Mar 31, 2026	May 4, 2026	SEC EDGAR
Current report	8-K	May 4, 2026	May 4, 2026	SEC EDGAR
Proxy statement	DEF 14A	May 19, 2026	Apr 9, 2026	SEC EDGAR
Annual report	10-K	Dec 31, 2025	Feb 26, 2026	SEC EDGAR
Current report	8-K	Feb 26, 2026	Feb 26, 2026	SEC EDGAR
Quarterly report	10-Q	Sep 30, 2025	Nov 3, 2025	SEC EDGAR
Current report	8-K	Nov 3, 2025	Nov 3, 2025	SEC EDGAR
Current report	8-K	Sep 26, 2025	Oct 1, 2025	SEC EDGAR
Current report	8-K	Sep 12, 2025	Sep 15, 2025	SEC EDGAR
Current report	8-K	Sep 11, 2025	Sep 11, 2025	SEC EDGAR
Current report	8-K	Aug 7, 2025	Aug 7, 2025	SEC EDGAR
Quarterly report	10-Q	Jun 30, 2025	Aug 7, 2025	SEC EDGAR
Current report	8-K	May 20, 2025	May 21, 2025	SEC EDGAR
Quarterly report	10-Q	Mar 31, 2025	May 13, 2025	SEC EDGAR
Current report	8-K	May 13, 2025	May 13, 2025	SEC EDGAR
Proxy statement	DEF 14A	May 20, 2025	Apr 28, 2025	SEC EDGAR
Current report	8-K	Apr 15, 2025	Apr 17, 2025	SEC EDGAR
Current report	8-K	Mar 24, 2025	Mar 28, 2025	SEC EDGAR
Annual report	10-K	Dec 31, 2024	Mar 3, 2025	SEC EDGAR
Current report	8-K	Mar 3, 2025	Mar 3, 2025	SEC EDGAR
Current report	8-K	Jan 10, 2025	Jan 10, 2025	SEC EDGAR
Quarterly report	10-Q	Sep 30, 2024	Nov 1, 2024	SEC EDGAR
Current report	8-K	Nov 1, 2024	Nov 1, 2024	SEC EDGAR
Current report	8-K	Aug 14, 2024	Aug 15, 2024	SEC EDGAR
Quarterly report	10-Q	Jun 30, 2024	Aug 7, 2024	SEC EDGAR
Current report	8-K	Aug 7, 2024	Aug 7, 2024	SEC EDGAR
Current report	8-K	May 21, 2024	May 23, 2024	SEC EDGAR
Quarterly report	10-Q	Mar 31, 2024	May 8, 2024	SEC EDGAR
Current report	8-K	May 8, 2024	May 8, 2024	SEC EDGAR
Proxy statement	DEF 14A	May 21, 2024	Apr 26, 2024	SEC EDGAR
Current report	8-K	Apr 5, 2024	Apr 9, 2024	SEC EDGAR
Annual report	10-K	Dec 31, 2023	Mar 1, 2024	SEC EDGAR
Current report	8-K	Mar 1, 2024	Mar 1, 2024	SEC EDGAR
Current report	8-K	Dec 15, 2023	Dec 20, 2023	SEC EDGAR

Where these numbers come from

Parsed from the XBRL in Biodesix's annual and quarterly filings with the SEC
Per-share figures adjusted for the 1-for-20 reverse split on Sep 15, 2025
Fourth quarters derived from the annual report minus nine months
Every figure in the statements links to its source filing

Against peers

Trailing twelve months. Peers are matched on business description, industry and size. Ticks are peers, the dot is BDSX.

Compare: BDSX vs MDXH · BDSX vs PSNL · BDSX vs CSTL · BDSX vs XGN · BDSX vs GRAL

Revenue growth31.2% · median 15.3%

Operating margin-18.7% · median -88.4%

Net margin-25.7% · median -86.4%

Company	Revenue	Growth
CSTL	$377.13M	+9.8%
GRAL	$166.60M	+17.5%
BDSX	$105.21M	+31.2%
PSNL	$80.77M	+16.9%
XGN	$72.30M	+13.7%
MDXH	–	–

Company

Next earnings (est.): Feb 25, 2027, after close
Exchange: Nasdaq
Industry: Services-Medical Laboratories
Fiscal year ends: December 31
Employees: 334
Held by institutions: 41.4%
Auditor: KPMG LLP
SEC CIK: 1439725

Advertisement
300 × 250

See a number that looks wrong?